

## CURRICULUM VITAE

## Personal Information

<b>Title</b>	Professor	
<b>Name</b>	So Yeon Kim	
<b>Degree</b>	M.D., Ph.D.	
<b>Country</b>	Republic of Korea	
<b>Affiliation</b>	University of Ulsan College of Medicine, Asan Medical Center	
<b>Department</b>	Department of Radiology	

## Educational Background

1993–1999 M.D., University of Ulsan College of Medicine, Korea  
 1999–2000 Internship, Asan Medical Center, Seoul, Korea  
 2002–2006 Residency in Radiology, Asan Medical Center, Seoul, Korea  
 2006–2008 Fellowship in Abdominal Radiology, Asan Medical Center, Seoul, Korea  
 2009–2012 Ph.D. in Medicine, University of Ulsan College of Medicine, Korea

## Professional Career

2008–2010 Clinical Instructor in Abdominal Radiology, Seoul National University Bundang Hospital, Bundang, Korea  
 2010–2011 Assistant Professor in Abdominal Imaging, Seoul National University Bundang Hospital, Bundang, Korea  
 2011–2016 Assistant Professor in Abdominal Imaging, Asan Medical Center, Seoul, Korea  
 2013–2014 Visiting Professor, Department of Radiology and Biomedical Imaging, University of California—San Francisco (UCSF)  
 2016–2021 Associate Professor in Radiology, Asan Medical Center, Seoul, Korea  
 2021–Present Professor in Radiology, Asan Medical Center, Seoul, Korea  
 2024–Present Director, Research Institute of Radiology, Asan Medical Center, Korea

## Research Field

- Hepatobiliary and pancreatic imaging (CT, MRI, ultrasonography)
- Hepatocellular carcinoma (HCC) surveillance and early detection (including abbreviated MRI strategies)
- Quantitative imaging for diffuse liver disease (hepatic fat and fibrosis assessment)
- Image-guided liver tumor ablation (RFA, MWA, cryoablation) and treatment response assessment
- Imaging-based diagnostic algorithms and standardized reporting

## Main Scientific Publications

**Main Achievements (10 max)**

1. Park HJ, Kang HJ, Kim SY, et al. Effects of hepatic fibrosis on the quantification of hepatic steatosis using the controlled attenuation parameter in patients with chronic hepatitis B. *Ultrasonography* 2025;44(1):83–91.
2. Park HJ, Choi J, Kim DW, et al. Abbreviated gadoxetic acid–enhanced MRI versus ultrasonography for HCC surveillance in high-risk patients: A randomized trial protocol. *Hepatology Communications* 2025;9(12):e0839.
3. Kim HY, Hong S, Heo S, et al. Comparison of clinical and MRI features of hepatic angiosarcoma and epithelioid hemangioendothelioma. *Abdom Radiol (NY)* 2025;50(2):619–632.
4. Kim DW, Chang W, Kim SY, et al. Non-contrast magnetic resonance imaging for detection of late recurrent hepatocellular carcinoma after curative treatment: a prospective multicenter comparison to contrast-enhanced computed tomography. *Clin Mol Hepatol* 2025;31(4):1285–1297.
5. Heo S, Kim B, Kim SY, et al. A Multicenter Study on Hepatocellular Adenomas in Korea: Clinicopathological and Imaging Features With an Emphasis on  $\beta$ -Catenin Mutated Subtype. *Liver Int* 2025;45(4):e16155.
6. Endrikat J, Bogosavljev B, Bhatti A, Forgia S, Fuksbrumer MS, Kim S. Clinical Safety of Gadoxetate Disodium: Insights From 20 Years of Use and More Than 12 Million Administrations. *Invest Radiol* 2025.
7. Park HJ, Kim SY, Lim Y-S. Magnetic Resonance Imaging-Based Surveillance of Hepatocellular Carcinoma: Current Status and Future Perspectives. *Current Hepatology Reports* 2023;22(3):83–94.
8. Jeong WK, Kang HJ, Choi SH, et al. Diagnosing Hepatocellular Carcinoma Using Sonazoid Contrast-Enhanced Ultrasonography: 2023 Guidelines From the Korean Society of Radiology and the Korean Society of Abdominal Radiology. *Korean J Radiol* 2023;24(6):482–497.
9. Shiina S, Tateishi R, Choi JI, et al. Asian Conference on Tumor Ablation Guidelines for Hepatocellular Carcinoma. *Liver Cancer* 2025;14(5):651–678.